Posted by Michael Wonder on 08 Jul 2021
FDA approves updated Aduhelm prescribing information to emphasise population studied in clinical trials
8 July 2021 - Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia.
Biogen and Eisai today announced the U.S. FDA has approved an updated label for Aduhelm (aducanumab-avwa) injection 100 mg/mL solution.
